News Focus
News Focus
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

Re: DewDiligence post# 13015

Thursday, 04/30/2015 9:24:10 AM

Thursday, April 30, 2015 9:24:10 AM

Post# of 20689
1Q15 US Copaxone sales were $732M; the 40mg formulation had a 66% volume share of the combined 20mg and 40mg doses at the end of the quarter, which equates to a dollar share in the low 60s (since Teva sells the 40mg product at a small discount to the 20mg product).

Among all MS drugs in the US market, Copaxone (20mg + 40mg) had a 32% NRx share and a 31% TRx share at the end of 1Q15.

http://finance.yahoo.com/news/teva-reports-first-quarter-2015-110000963.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”